BamSEC and AlphaSense Join Forces
Learn More

Marinus Pharmaceuticals Inc.

NASDAQ: MRNS    
Share price (12/27/24): $0.37    
Market cap (12/27/24): $20.5 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10
from 8-K 12 pages ​ Marinus Pharmaceuticals, Inc. Amended and Restated Change in Control Severance Plan
12/34/56
EX-10.8
from S-8 9 pages ​ Marinus Pharmaceuticals, Inc. 2024 Equity Incentive Plan Incentive Stock Option Agreement
12/34/56
EX-10.7
from S-8 9 pages ​ Marinus Pharmaceuticals, Inc. Inducement Award Nonqualified Stock Option Agreement
12/34/56
EX-10.6
from S-8 7 pages ​ Marinus Pharmaceuticals, Inc. 2024 Equity Incentive Plan Restricted Stock Unit Agreement
12/34/56
EX-10.5
from S-8 8 pages ​ Marinus Pharmaceuticals, Inc. 2024 Equity Incentive Plan Nonqualified Stock Option Agreement
12/34/56
EX-10.4
from S-8 6 pages ​ Marinus Pharmaceuticals, Inc. 2024 Equity Incentive Plan Restricted Stock Unit Agreement for Non-Employee Directors
12/34/56
EX-10.3
from S-8 8 pages ​ Marinus Pharmaceuticals, Inc. 2024 Equity Incentive Plan Nonqualified Stock Option Agreement for Non-Employee Directors
12/34/56
EX-10.2
from 8-K 6 pages First Amendment to Revenue Interest Financing Agreement
12/34/56
EX-10.1
from 8-K 32 pages Marinus Pharmaceuticals, Inc. 2024 Equity Incentive Plan
12/34/56
EX-10.7
from 10-K 11 pages Amended and Restated Indemnification Agreement
12/34/56
EX-10.1
from 8-K 3 pages Amendment No. 1 to the Equity Distribution Agreement
12/34/56
EX-10.42
from 10-K 48 pages Collaboration and Supply Agreement
12/34/56
EX-10.7
from 10-K 10 pages Amended and Restated Indemnification Agreement
12/34/56
EX-10.5
from 10-K 13 pages Employment Agreement ​ Employment Agreement Is Effective on November 9, 2020, Between Marinus Pharmaceuticals, Inc. (The “Company”), a Delaware Corporation, and Christina Shafer (The “Employee”). ​
12/34/56
EX-10.4
from 10-Q 52 pages Security Agreement
12/34/56
EX-10.3
from 10-Q 123 pages Revenue Interest Financing Agreement by and Between Marinus Pharmaceuticals, Inc., as the Company, and Sagard Healthcare Royalty Partners, LP, as the Investor Dated October 28, 2022
12/34/56
EX-10.1
from 8-K 12 pages Material contract
12/34/56
EX-10.1
from 8-K 35 pages ​ ​ ​ ​ ​ Asset Purchase Agreement by and Between Novo Nordisk Inc. and Marinus Pharmaceuticals, Inc. Dated as of July 13, 2022
12/34/56
EX-10.1
from 8-K 11 pages Letter Agreement Re: Amendments to the Tranche C Commitment
12/34/56
EX-10.1
from 8-K 2 pages Material contract
12/34/56